Research programme: cancer therapeutics - Redx Pharma

Next Previous
Drug Profile

Research programme: cancer therapeutics - Redx Pharma

Alternative Names: Bruton's tyrosine kinase inhibitor - Redx Pharma; Indoleamine-2,3-dioxygenase inhibitor - Redx Pharma; REDX 05358; REDX 08608; SHP2 inhibitors - Redx Pharma; Smoothened inhibitor - Redx Pharma; T-cell target agonists - Redx Pharma

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Redx Pharma
  • Developer Horizon Discovery; Redx Pharma
  • Class Small molecules
  • Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists; Raf kinase inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Basal cell cancer
  • Research Colorectal cancer; Solid tumours

Most Recent Events

  • 17 Oct 2017 Early research in Solid tumours in United Kingdom before October 2017 (Redx Pharma pipeline, October 2017)
  • 03 Dec 2016 Pharmacokinetics data from a preclinical study in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 29 Nov 2016 Preclinical data presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top